Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Shefner

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Muscle & Nerve|September 19, 2024
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosisJames D Berry, Sabrina Paganoni, Matthew B Harms, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 15, 2019
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosisSuma Babu, Eric A Macklin, Katherine E Jackson, et al.
Muscle & Nerve|June 29, 2026
At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform TrialEric A Macklin, James D Berry, Brittney A Harkey, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Brain : a Journal of Neurology|October 22, 2021
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseasesMichael Benatar, Joanne Wuu, Caroline McHutchison, et al.
Nature Reviews. Neurology|May 29, 2024
Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Nature Reviews. Neurology|May 20, 2024
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Annals of Neurology|September 11, 2009
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIPetra Kaufmann, John L P Thompson, Gilberto Levy, et al.
Neurology|January 13, 2023
Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface SystemDaniel B Rubin, A Bolu Ajiboye, Laurie Barefoot, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Muscle & Nerve|September 19, 2024
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosisJames D Berry, Sabrina Paganoni, Matthew B Harms, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 15, 2019
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosisSuma Babu, Eric A Macklin, Katherine E Jackson, et al.
Muscle & Nerve|June 29, 2026
At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform TrialEric A Macklin, James D Berry, Brittney A Harkey, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Brain : a Journal of Neurology|October 22, 2021
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseasesMichael Benatar, Joanne Wuu, Caroline McHutchison, et al.
Nature Reviews. Neurology|May 29, 2024
Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Nature Reviews. Neurology|May 20, 2024
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Annals of Neurology|September 11, 2009
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIPetra Kaufmann, John L P Thompson, Gilberto Levy, et al.
Neurology|January 13, 2023
Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface SystemDaniel B Rubin, A Bolu Ajiboye, Laurie Barefoot, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Pageof 6